The focus of cancer immunotherapies is, by leveraging the immune system, to utilize the natural immunity to fight with cancer. Compared with traditional therapies, monoclonal antibody-based immunotherapy is thought to be more advantageous. As a thriving CRO, Creative Biolabs Next-IO™ team is dedicated to developing and accelerating novel therapeutic mAb programs with the hope of our partners. This anti-KIR2DL4 mAb program aims to develop therapeutic mAb against KIR2DL4 that could potentially restore the cytotoxicity activity of NK cells.
Killer cell Ig-like receptors (KIRs) can recognize major histocompatibility complex class I (MHC-I) molecules and able to modulate natural killer (NK) cell function in both positive and negative manners. KIR2DL4 (CD158d), a member of the KIR family, is expressed in all NK cells and some T cells. KIR2DL4 has an ITIMs-motif-containing cytoplasmic domain that could transmit suppressive signals to NK cells. Its ligand is HLA-G (see Fig.1). Studies have shown that HLA-G can upregulate tumor-promoting agents in various cancer and its ligation with KIR2DL4 accelerates tumor evasion. The inhibitory signals transduced by KIR2DL4 are mediated by Src homology region 2 domain-containing phosphatase (SHP)-1 and SHP-2 domains.
Studies show KIR2DL4 in human mast cells contribute to tumor metastasis and invasion of HLA-G-positive cancer cells. Also, KIR2DL4 is expressed on NK cell lymphoma and neoplastic mast cells. On the other hand, HLA-G plays the inhibitory role in cancer development via the ligation with KIR2DL4. These findings endorse KIR2DL4 may be a potential therapeutic target to research cancers. From this, we develop this therapeutic mAb program against KIR2DL4 to suppress the inhibitory signals in NK cells and restore the cytotoxicity reactions. We are dedicated to pushing the anti-KIR2DL4 immunotherapy forward to the pre-IND as soon as possible. Other than monoclonal antibody developments, we also open to co-develop combination strategies, and other antibody modalities, such as a bispecific antibody, etc.
From the data, we learn that the KIR2DL4 acts as a potential therapeutic receptor expressed on NK cells. For any additional assistance, please feel free to reach out to our scientists.
We have extensive experience in performing comprehensive program developments and effective problem-solving. For our Next-IO™ programs, we are committed to promoting the program to the pre-IND stage within about 1.5 years. The accurate timeline will be determined on a case-by-case basis. Here is a draft timeline for your glance.
Fig.1 The timeline of Next-IOᵀᴹ programs.
Creative Biolabs is looking for potential partners and collaboration opportunities to co-develop anti-KIR2DL4 antibody program. We offer trusted partnerships to partners all over the world. We are committed to forward the project as soon as possible to ensure timely delivery. We will acknowledge and share the potential risks with our clients together. We firmly believe the powerful collaboration will unleash the creative spirit and help both parties reach new horizons in the field of immuno-oncology.
If you are interested in the collaborations, please don’t hesitate to contact us to learn more.
For Research Use Only | Not For Clinical Use
Download our brochure